1. Gabow PA. Autosomal Dominant Polycystic Kidney Disease. N Engl J Med 1993; 22(4h332-342.
2.
Ere
k E, Serdengeyli K, Süleymanlar G. Türkiye de Nefroloji Diyaliz ve Transplantasyon, Türk Nefroloji Derneği Yayınları. İstanbul 2004.
3. Johnson A, Gabow P. Identification of patients with autosomal dominant polycystic: kidney disease at highest risk for end-stage renal disease.J Am Soc Nephrol. 1997; 8:1560-7.
4. Massy ZA. Guijarro G, Kasiske BL. Plasma mevalonate and its importance in nephrology. Nephrol Dial Transplant 1994; 9: 17 Id-18.
5. Corilsidis G, Rifiri V, Gupta S, et al. Preferal binding of oxidized LDL to rat glomeruli in vivo and cultured mesangial cells in vitro. Kidney Int 1991; 39: 858-866.
6. Nogaki F, Muso F. Yashiro M, et al. Direct inhibitory effects of simvastatin on matrix accumulation in cultured murine mesangial cells. Kidney Int 1999; 56, Suppl.71: 198-201.
7. Wheeler IX], Persaud W, Fernando R, et al. Effects of Low-Density lipoproteins on mesangial cell growth and viability in vitro. Nephrol Dial Transplant 1990; 5: 185-191.
8. Rovin BH. Tan BC. LDL stimulates mesangial fibronectin production and chemoattractant expression. Kidney Int 1993; 43; 218-225.
9. Kim SY, Guijarro C. O'Donnell MP, et al. Human mesangial
cell production of monocyte chemoattractant protein-1; Modulation by lovastatin. Kidney Ini 1995; 48: 363-371.
10. Grandaliano G, Biswas P, Choudhury GG, Abboud HE. Simvastatin inhibits PDGF-induced DNA synthesis in human mesangial cells. Kidney Int 1993; 44: 503-508.
11. Laufs U, Fata VL, Piutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG GoA reductase inhibitors. Circulation 1998; 97: 1129-1135.
12. Kaesemeyer WH, Caldwell RB, Huang J, Caldwell RW. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. J Am Coll Cardiol. 1999 jan;33(D:234-41.
13- O'Driscoll G, Green D, Taylor RR. Simvastatin, an E IMG-co-enzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation. 1997 Mar 4;95(5): 1126-31.
14. Glazer AA, Inman SR, Stowe NT, Novick AC. Renal microcir-culatory effects of lovastatin in a rat model of reduced renal mass. Uroiogy. 1997 Nov;50(5):812-7.
15. Stowe NT, Inman SR, Tapolyai M, et al. Lovastatin has direct renal hemodynamic effects in a rodent model. J Urol. 1996 Jul; 156(1): 249-52.
16. Jiang J, Roman RJ. Lovastatin prevents development of hypertension in spontaneously hypertensive rats. Hypertension. 1997 Oct;30(4):968-74.
17. Lee SK, Jin SY, Han DC, et al. Effects of delayed treatment with enaiapril and/or lovastatin on the progression of glomerulosclerosis in 5/6 nephrectomized rats. Nephrol Dial Transplant. 1993;8(12):1338-43.
18. O'Donnell MP, Kasiske BL, Kim Y, el al. Lovastatin retards the progression of est ablished glomerular disease in obese Zucker rats. Am J Kidney Dis. 1993 Jul;22( 11:83-9.
19. Hafez KS, Inman SR, Stowe NT, Novick AC. Renal hemodynamic effects of lovastatin in a renal ablation model. Urology. 1996 Dec;48(6) :862-7.
20. Jiang J, Sun CW, Alonso-Galicia M, Roman RJ. Lovastatin reduces renal vascular reactivity in spontaneously hypertensive rats. Am J Hypertens. 1998 Oct;ll(10):1222-31.
21. van Dijk MA, Kamper AM, van Veen S. et al. Effect of simvastatin on renal function in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant. 2001; 16: 2152-57.
22. Stroes ES, Koomans HA, de Bruin TW, Rabclink TJ. Vascular function in the foreann of hypercholesterolaemic patients off and on lipid-iowering medication. Lancet. 1995 Aug 19;346(8973):467-71.
23. O'Donnell MP, Kasiske BL, Kİm Y, el al. Lovastatin inhibits proliferation of rat mesangial cells. J Clin Invest. 1993 Jan: 9KD:83-7.
24. Iimura O, Vttovsnik F, Terzi F, Kriedlander G. HMG-CoA reductase inhibitors induce apoprosis in mouse proximal tubular cells İn primary culture. Kidney Int. 1997 Oct;52(4):962-72.
25. Gattone VH 2nd, Wang X, Harris PC, Torres VE. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med. 2003 Oci;9(10): 1323-6. Epub 2003 Sep 21.
26. Ogborn MR, Nitschmann E, Weiler HA, Bankovic-Calic N. Modification of polycystic kidney disease and fatty acid status by soy protein diet. Kidney Int. 2000 Jan;57(l):159-66.
27. Ogborn MR, Bankovic-Calic N, Shoesmith C, Buist R, Peeling J. Soy protein modification of rat polycystic kidney disease. Am J Physiol. 1998 Mar;274(3 Pt 2):E54l-9.
28. Obermuller N, Morente N, Kranzlin B, et al. A possible role for metalloproteinases in renal cyst development. Am J Physi-
38
Türk
Nefroloj
i Diyaliz ve Transplantasyon Dergisi /Official Journal of the Turkish Society of Nephrology
Otozomal Dominant
PoIİklstl
k Böbrek Hastalığı Tedavisinde Yeni Ufuklar 9
ol Renal Physiol, 2tMH Mar,28Q(3):F54O-50.
29. Woo DD. Miao SY, PelayoJC, Woolf AS. Taxol inhibits progression of conge nil Li I polycystic kidney disease. Nature. 1994 Apr 21:5<>H<(w73):7Sl>-3.
30. Martinez JR. Cowley BD, Gaitone V H 2nd, et al. Tlie effect of paclitaxel on the progression of polycystic kidney disease in rodents. Anı J Kidney Dis. 1997 Mar;29<3>:-i35-44.
31. Muto S. Aiba A. Saito Y, et al. Pioglitazone improves the phe-notype and molecular defects of a targeted Pkdl mutant. Hum Mol Genet. 2002 Jut 15;11( 15): 1731-42.
32. Sweeney WF. Jr, fiamahira K. Sweeney J, et al. Combination treatment of PKD ulili/.ing dual inhibition of EGF-receptor activity and ligand hioavailahiliiy Kidney Int. 2003 <>Ct;:1310-9.
33. Torres VK, el al. F.GF receptor tyrosine kinase inhibition is not protective in PCK rats. Kidney Int. 2004 ;66 (5): 1766-73-
34. Tanner GA, Tanner JA. Dietary citrate treatment of polycystic kidney disease in rats. Nephron Physiol. 2003 Jan;93(D:P14-2<).
35. Ostrom L, Tang MJ, Gruss P, Dressier GR. Reduced Pax2 gene dosage increases apoptosis and slows the progression of renal cystic disease. Dev Biol. 2000 Mar 15;219<2):250-8.
36. Yamaguchi T, et al. Calcium restores a normai proliferation phenotype in human polycystic kidney disease epithelial cells, J Am Soc Nephrol.2006 Jan; 17(l):178-87).
37. Wahl PR, et al. Inhibition of mTOR with sirolimus slows disease progression in HamSPRD rats with ADPKD. Nephrol Dial Transplant. 2006; 21 (3>:598-604.
38. Tao Y, et al. Rapamycin markedly slows disease- progression in a rat model of polycystic kidney disease. J Am Soc Nephrol. 2005 ; 16(1):46-51.
39. Ruggenenti P, et al. Safety and efficacy of long-acting somatostatin treatment in ADPKD.Kidney Int. 2005 ; 68 (1) :206-l6.
Thank you for copying data from http://www.arastirmax.com